[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100370332":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":36,"locations":42,"responsibleParty":89,"collaborators":91,"id":106,"slug":107,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":10,"eligibilityCriteria":112,"healthyVolunteers":108,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":10,"studyType":119,"phases":10,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Pacific Parkinson's Research Centre","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"GBA-PD",null,"People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.",[13,14],"Diagnostic Test: PET scan","Diagnostic Test: neuroQWERTY",{"label":16,"type":10,"description":17,"interventionNames":18},"Asymptomatic GBA","Known heterozygous carriers\u002Fobligated carriers of pathogenic GBA gene mutations.",[13,14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DIAGNOSTIC_TEST","PET scan","3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.",[16,9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"neuroQWERTY","Analysis of free-text typing in a computer and\u002For a touch-screen device.",[16,9],[30,34],{"name":31,"affiliation":32,"role":33},"Michele Matarazzo, MD","Pacific Parkinson's Research Centre | University of British Columbia","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":32,"role":33},"A. Jon Stoessl, CM, MD, FRCPC, FCAHS",[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Jessamyn McKenzie","CONTACT","6048227764","jess.mckenzie@ubc.ca",[43,60,73],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Oregon Health & Science University","RECRUITING","Portland","Oregon","97239","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-122.67621,45.52345,{"lat":55,"lon":54},[58],{"name":59,"role":33,"phone":10,"phoneExt":10,"email":10},"Matthew Brodsky, MD",{"facility":61,"status":45,"city":62,"state":63,"zip":64,"country":49,"countryCode":50,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"University of Washington","Seattle","Washington","98108-1595",{"type":52,"coordinates":66},[67,68],-122.33207,47.60621,{"lat":68,"lon":67},[71],{"name":72,"role":33,"phone":10,"phoneExt":10,"email":10},"Cyrus P Zabetian, MD, MS",{"facility":32,"status":45,"city":74,"state":75,"zip":10,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Vancouver","British Columbia","Canada","CA",{"type":52,"coordinates":79},[80,81],-123.11934,49.24966,{"lat":81,"lon":80},[84,87],{"name":85,"role":39,"phone":86,"phoneExt":10,"email":41},"Jess McKenzie","+1-604-822-7764",{"name":88,"role":33,"phone":10,"phoneExt":10,"email":10},"A Jon Stoessl, MD",{"type":90,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[92,94,95,97,99,101,104],{"name":93,"class":6},"University of British Columbia",{"name":61,"class":6},{"name":96,"class":6},"Oregon Health and Science University",{"name":98,"class":6},"Simon Fraser University",{"name":100,"class":6},"Michael J. Fox Foundation for Parkinson's Research",{"name":102,"class":103},"Silverstein Foundation","UNKNOWN",{"name":105,"class":6},"Weston Brain Institute","100370332","the-gba-multimodal-study-in-parkinsons-disease-100370332",false,"NCT04101968","The GBA Multimodal Study in Parkinson's Disease","Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers","Inclusion Criteria:\n\n* heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;\n* age 18 to 80 years.\n\nExclusion Criteria:\n\n* co-occurrence of other neurological disorders;\n* implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);\n* severe claustrophobia;\n* intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);\n* ongoing treatment with cholinergic drugs","ALL","18 Years","80 Years",{"count":117,"type":118},25,"ESTIMATED","OBSERVATIONAL","This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.",[122,123,124],"Parkinson Disease","GBA Gene Mutation","Gaucher Disease",[126],"Parkinson","2025-05-27",{"date":129,"type":130},"2025-05-31","ACTUAL",{"date":132,"type":130},"2019-05-01",{"date":134,"type":118},"2025-12-30",{"name":5,"class":6},3]